Treatment-free interval as a metric of patient experience and a health outcome of value for advanced multiple myeloma: the case for the histone deacetylase inhibitor panobinostat, a next-generation novel agent.
about
Treatment-free interval as a metric of patient experience and a health outcome of value for advanced multiple myeloma: the case for the histone deacetylase inhibitor panobinostat, a next-generation novel agent.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh-hant
name
Treatment-free interval as a m ...... a next-generation novel agent.
@en
Treatment-free interval as a m ...... a next-generation novel agent.
@nl
type
label
Treatment-free interval as a m ...... a next-generation novel agent.
@en
Treatment-free interval as a m ...... a next-generation novel agent.
@nl
prefLabel
Treatment-free interval as a m ...... a next-generation novel agent.
@en
Treatment-free interval as a m ...... a next-generation novel agent.
@nl
P2093
P2860
P50
P1476
Treatment-free interval as a m ...... a next-generation novel agent.
@en
P2093
Andreas Günther
Ashok Panneerselvam
Estella Mendelson
Suddhasatta Acharyya
P2860
P304
P356
10.1080/17474086.2017.1369399
P577
2017-09-08T00:00:00Z